A biotech investment with a twist
This closed-end fund offers exposure to both publicly traded and venture capital plays in the space.
H&Q Life Sciences (HQL) is a closed-end fund that specializes in the biotechnology sector; it offers the potential for long-term growth with a substantial income kicker.
It's very different from the average health care fund. First, it largely specializes in the biotechnology sector, so its investments are generally riskier than some of the more traditional health care stocks.
Biotech stocks, including well-known names such as Gilead Sciences (GILD) and Celgene (CELG), were nearly 60% of its assets.
Almost a third of the fund's equity sleeve was allocated toward small- and mid-cap stocks. And the fund also had a substantial 12.7% allocation to micro-cap stocks. And the fund bets heavily on its favorites, with 48.3% of assets in its top 10 holdings.
And because it's a closed-end fund, HQL has fewer constraints on its investments than a traditional mutual fund. For instance, HQL is permitted to invest up to 40% of its assets in venture or restricted securities.
In other words, the fund not only invests in cutting-edge stocks, it also has a venture capital sleeve that offers exposure to firms that may not even be public yet.
Fortunately, management knows how to navigate this risky space. The two principal portfolio managers both have doctorates and extensive industry experience.
Lead manager Daniel Omstead was previously president and CEO of a development-stage biotech company that specialized in regenerative medicine, and prior to that spent 14 years in the pharmaceutical industry.
And Frank Gentile worked in both the pharmaceutical and biotech industries and holds 30 U.S. patents in the biotech realm. Both have been with the fund for well over a decade and work alongside two other analysts with similar backgrounds and longevity with the fund.
This rare combination of experience and financial acumen has translated into an impressive performance in recent years, with the portfolio gaining 32.6% over the past three years.
HQL has a managed distribution policy under which it makes a quarterly payout that's equivalent to 2% of net assets.
The distribution can consist of short- or long-term capital gains, dividends from equity investments, interest from fixed-income investments, and occasionally the dreaded return of capital. So the tax consequences of the fund's distributions will vary over time.
HQL currently trades at nearly a 4% discount to NAV, so we're setting our buy target based upon a 3% discount to the fund's NAV on Sept. 19, which was $20.38. Buy HQL below $19.77.
More from MoneyShow.com
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
John Stumpf acknowledges that growth has been slow, but he says he's still optimistic.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.